On December 17, 2020, CHI Memorial Hospital nurse manager Tiffany Dover became one of the first American healthcare workers to receive Pfizer's novel mRNA-based COVID-19 vaccine.

With media crews on hand recording the public event, Dover was presented to the public for a post-injection interview with the hopes to promote future uptake in a product that was then considered a possible cure to the coronavirus.

"It's been a hard time," Dover said about the last year. "We've persevered through it, but I think that this vaccination offers us hope."

Suddenly, Dover's demeanor changed. "I'm sorry, I'm feeling a little dizzy," she added, holding her head, before fainting onto the ground.

After she was brought back to consciousness, a clearly shaken Dover later told the media that she regularly has an over-reactive vagal response (half a dozen recent fainting spells, she said), and added that was why she collapsed onto the ground after taking the shot.

Sure, It was a perplexing situation, as one could certainly question the wisdom of CHI Memorial sending someone with a known fainting condition for a post-injection live press conference. Nonetheless, at the time, it could be written off to simple bureaucratic foolishness.

With tens of billions of dollars in revenue on the line, and a "safe and effective" stamp of approval from the U.S. government, this was not the launch of a widespread marketing campaign that Pfizer and the Public Health establishment had hoped for.

But that was just the beginning of the Tiffany Dover mystery.